Arcus Biosciences, Inc. (RCUS) Financial Statements (2024 and earlier)

Company Profile

Business Address 3928 POINT EDEN WAY
HAYWARD, CA 94545
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,009,000499,308173,41557,93771,064
Cash and cash equivalents206,000147,914173,41557,93771,064
Short-term investments803,000351,394   
Receivables4,0002,2271,592 83
Contract with customer, asset, after allowance for credit loss39,000744,5951,049132 
Other undisclosed current assets15,00015,620559,759134,636187,801
Total current assets:1,067,0001,261,750735,815192,705258,948
Noncurrent Assets
Operating lease, right-of-use asset  104,96812,781 
Property, plant and equipment35,00032,45510,8079,33011,107
Long-term investments and receivables129,000181,9906,440 1,202
Long-term investments129,000181,9906,440 1,202
Restricted cash and investments  3,005203203203
Other noncurrent assets114,0007,7306,246872284
Other undisclosed noncurrent assets     3,181
Total noncurrent assets:278,000330,14836,47710,40515,977
TOTAL ASSETS:1,345,0001,591,898772,292203,110274,925
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities20,00052,90533,85714,2269,125
Taxes payable1,815   
Employee-related liabilities16,6488,632  
Accounts payable20,00010,26115,6824,7043,102
Accrued liabilities  24,1819,5439,5226,023
Deferred revenue97,000102,00374,5717,000
Other liabilities76,000523,5661,4801,560
Other undisclosed current liabilities  11,1249,675 6,250
Total current liabilities:193,000166,084121,66922,70616,935
Noncurrent Liabilities
Long-term debt and lease obligation:  116,88715,243  
Liabilities, other than long-term debt495,000467,477133,07616,5626,064
Deferred revenue355,000462,217122,83012,022
Deferred rent credit    3,7344,272
Other liabilities140,0005,26010,2468061,792
Operating lease, liability  116,88715,243 
Other undisclosed noncurrent liabilities     16,984
Total noncurrent liabilities:495,000584,364148,31916,56223,048
Total liabilities:688,000750,448269,98839,26839,983
Equity
Equity, attributable to parent657,000841,450502,304163,842234,942
Common stock1,206,0007644
Additional paid in capital  1,118,058830,438369,100357,873
Accumulated other comprehensive income (loss) (7,000)(1,261)4464(107)
Accumulated deficit(542,000)(275,354)(328,184)(205,326)(122,828)
Total equity:657,000841,450502,304163,842234,942
TOTAL LIABILITIES AND EQUITY:1,345,0001,591,898772,292203,110274,925

Income Statement (P&L) ($ in thousands)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues112,000382,88277,51715,0008,353
Gross profit:112,000382,88277,51715,0008,353
Operating expenses(392,000)(328,634)(201,752)(103,709)(63,212)
Operating income (loss):(280,000)54,248(124,235)(88,709)(54,859)
Nonoperating income14,0003971,3773,9995,265
Income (loss) from continuing operations before equity method investments, income taxes:(266,000)54,645(122,858)(84,710)(49,594)
Loss from equity method investments   (613)  
Income (loss) from continuing operations before income taxes:(266,000)54,645(123,471)(84,710)(49,594)
Income tax expense(1,000)(1,815)   
Income (loss) from continuing operations:(267,000)52,830(123,471)(84,710)(49,594)
Income (loss) before gain (loss) on sale of properties:52,830(123,471)(84,710)(49,594)
Other undisclosed net income   613  
Net income (loss) available to common stockholders, diluted:(267,000)52,830(122,858)(84,710)(49,594)

Comprehensive Income ($ in thousands)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net income (loss):(267,000)52,830(122,858)(84,710)(49,594)
Other comprehensive income (loss)(6,000)(1,305)(20)171(65)
Comprehensive income (loss), net of tax, attributable to parent:(273,000)51,525(122,878)(84,539)(49,659)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: